

References

I-148

1. Verdaguer H, Tabernero J, Marcarulla T. Ramucirumab in metastatic colorectal cancer: Evidence to date and place in therapy. *Ther Advan Med Oncol*. 2016;8(3):230-242.
2. Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. *Eur J Cancer*. 2017;(81):17-25.
3. Yoshino T, Obermannova R, Bodoky G. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. *Eur J Cancer*. 2017;(78):61-69.
4. Grabowski J, Glode A. Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies. *Am J Health-Syst Pharm*. 2016;(73)13:957-68.
5. Cohn AL, Yoshino T, Heinemann V, et al. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: Exploratory analysis of the RAISE trial. *Cancer Chemother Pharmacol*. 2017;80(3):599-608.
6. Chau I, Park JO, Ryoo B-Y, et al. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study. *Br J Cancer*. 2018;119(1):19-26.
7. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomized, double-blind, phase 3 trial. *The Lancet*. 2017;390(10109):2266-2277.
8. Ramalingam SS, Porol M, Reck M, et al. Efficacy and safety of ramucirumab with docetaxel versus placebo with docetaxel as second-line treatment of advanced non-small-cell lung cancer: A subgroup analysis according to patient age in the REVEL trial. *Clin Lung Cancer*. 2018;19(3):270-279.
9. Kudo M, Galle PR, Llovet JM, et al. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. *Liver Cancer Int*. 2020;40(8):2008-2020.
10. Kawai S, Fukuda N, Yamamoto S, et al. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. *BMC cancer*, 2020;20:1-9.
11. Ramucirumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 7, 2017.

12. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Ramucirumab.
13. Micromedex DrugDex Compendium®. 2024. Ramucirumab.
14. National Comprehensive Cancer Network (NCCN). Ramucirumab. NCCN Drugs and Biologics Compendium®. 2024.
15. Cyramza (ramucirumab) injection, for intravenous use [package insert]. Eli Lilly and Company. Indianapolis, IN. Revised 03/2022.